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Background: Cardiac dysfunction in diabetic cardiomyopathy may be associated with abnormal Ca2+ homeostasis.
This study investigated the effects of alterations in Ca2+ homeostasis and sarcoplasmic reticulum Ca2+-associated
proteins on cardiac function in the development of diabetic cardiomyopathy.
Methods: Sprague–Dawley rats were divided into 4 groups (n = 12, each): a control group, and streptozotocin-induced
rat models of diabetes groups, examined after 4, 8, or 12 weeks. Evaluations on cardiac structure and function were
performed by echocardiography and hemodynamic examinations, respectively. Cardiomyocytes were isolated and
spontaneous Ca2+ spark images were formed by introducing fluorescent dye Fluo-4 and obtained with confocal
scanning microscopy. Expressions of Ca2+-associated proteins were assessed by Western blotting.
Results: Echocardiography and hemodynamic measurements revealed that cardiac dysfunction is associated with
the progression of diabetes, which also correlated with a gradual but significant decline in Ca2+ spark frequency
(in the 4-, 8- and 12-week diabetic groups). However, Ca2+ spark decay time constants increased significantly, relative
to the control group. Expressions of ryanodine receptor 2 (RyR2), sarcoplasmic reticulum Ca2+-2ATPase (SERCA) and
Na+/Ca2+ exchanger (NCX1) were decreased, together with quantitative alterations in Ca2+regulatory proteins, FKBP12.6
and phospholamban progressively and respectively in the diabetic rats.
Conclusions: Ca2+ sparks exhibited a time-dependent decay with progression of diabetic cardiomyopathy, which may
partly contribute to cardiac dysfunction. This abnormality may be attributable to alterations in the expressions of some
Ca2+-associated proteins.
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Ca2+-induced Ca2+ release plays an important role in the
translation of electrical signals to physical contraction in
cardiomyocytes, known as excitation-contraction coup-
ling. A small amount of Ca2+ influx through L-type Ca2+
channels can activate a further discharge of Ca2+ from
the sarcoplasmic reticulum (SR) via ryanodine receptor
2 (RyR2), resulting in an increase in global intracellular
Ca2+ which activates contraction [1]. Elementary Ca2+
release events occur spontaneously as clusters, termed
Ca2+ sparks [2]. During diastole, myocardial relaxation
results from the reuptake of Ca2+ into the SR via
Ca2+-ATPase (SERCA) on the SR, and concurrently
Ca2+ is pumped out of the cardiomyocytes via the* Correspondence: yd678182@163.com
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unless otherwise stated.Na+/Ca2+ exchanger (NCX). An imbalance of Ca2+ flux
may induce pathological conditions such as arrhythmia
and decreased contractility of the cardiomyocytes. It
has been reported that a certain portion of the con-
tractile deficit in heart failure is due to an impairment
of Ca2+ homeostasis [3,4].
Diabetic cardiomyopathy was initially recognized by
Rubler et al. [5] in diabetic patients, who exhibited
defects in myocardial contraction and relaxation, and
increased morbidity and mortality. Cardiac dysfunction
in diabetic models may result from a variety of metabolic
and biochemical abnormalities, including abnormal Ca2+
homeostasis. As shown in a previous study, the ability of
Ca2+ current to trigger SR Ca2+ release is decreased sig-
nificantly in diabetic cardiomyocytes. Spontaneous Ca2+
spark frequency and peak amplitude were also both
significantly reduced (P < 0.05) in diabetic myocytestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Choi KM et al. [7] found that the SR Ca2+ release rate
and Ca2+ stores were depressed in the cardiomyocytes of
type 1 diabetic rats. These changes may account for
cardiac dysfunction in diabetic models. However, incon-
sistent results have been reported. For instance, accord-
ing to Yaras et al. [8] the maximal amplitude of Ca2+
sparks was not significantly changed, but the spon-
taneous Ca2+ spark frequency was elevated in diabetic
cardiomyocytes, compared with control cells.
It is obvious that the role of Ca2+ involvement in diabetic
cardiomyopathy is still not fully known and requires fur-
ther investigation. As animal models in different diabetic
stages have been used in various studies, we hypothesized
that the inconsistent results regarding Ca2+ homeostasis
were due to different severities and stages of diabetes.
Therefore, this study investigated the progressive
alterations in Ca2+ homeostasis and expressions of SR
Ca2+- associated proteins in the development of diabetes,
and the association between Ca2+ homeostasis and cardiac
dysfunction in diabetic cardiomyopathy.
Methods
Animal models
The Beijing Friendship Hospital Animal Care Committee
approved all animal handling protocols. The diabetic rat
model was induced with a single intraperitoneal injec-
tion of streptozotocin (60 mg/kg diluted in 0.1 M citrate
buffer, pH = 4.4; Sigma, USA) in male rats (Sprague–
Dawley; 200 ± 20 g). Rats in the control group were
given an injection of a matched volume of citrate buffer
(0.1 M). Subsequently on day three and day five after the
injection, random blood glucose concentrations were mea-
sured. Only rats with blood glucose levels ≥16.7 mmol/L
on both days were defined as diabetic and used in the
study.
Four experimental groups (n = 12, each) consisted of
the control group (group A) and the diabetic model rats,
examined at 4, 8, or 12 weeks after injection (groups B, C
and D, respectively). All the rats were housed (three per
cage) in a controlled environment at 20 ± 2°C, 30-70%
humidity, and a 12:12 h light–dark cycle, and given stand-
ard chow and water ad libitum. In accordance with the
protocol, all diabetic model rats were euthanized prior to
the experiments at the assigned time points. Control rats
were euthanized at the twelfth week after an injection with
citrate buffer.
Echocardiographic measurements
Echocardiography was performed to evaluate cardiac
structure and function in all animals involved in the study
(n = 12, in each group). The rats were weighed and anesthe-
tized with 10% chloral hydrate at 0.3 mL/100 g body weight
[9]. Two-dimensional and M-mode echocardiographicmeasurements were carried out with a VEVO 770 high-
resolution in vivo imaging system (VisualSonics, Toronto,
Canada). The transthoracic echocardiography images were
obtained via long- and short-axis views using standard
echocardiography techniques [10]. Cardiac structure was
principally evaluated by the left ventricular end diastolic
and systolic diameters. The left ventricular systolic
function was assessed according to ejection fraction and
fractional shortening, and the left ventricular diastolic
function was determined by Doppler waveforms of
mitral inflows, which were obtained from an apical
four-chamber. The variables included the peak early
diastolic filling velocity (E wave), the peak late diastolic
filling velocity (A wave), and the ratio of the peak early-
to late-filling velocity (E/A).
Hemodynamic measurements
To assess the hemodynamic condition, an ultra-miniature
catheter connected to a polygraph instrument (BL-420,
TaiMeng, ChengDu, China) was inserted into the carotid
artery, and then to the left ventricle of the anesthetized
animals (n = 6, in each group). After a 5-min period of
stabilization, the parameters were acquired and recorded.
The myocardial contractility was assessed according to the
left ventricular systolic peak pressure (LVPSP) and the
maximum rate of ascending pressure change in the left
ventricle (+dP/dtmax). Myocardial relaxation was evaluated
according to the left ventricular end-diastolic pressure
(LVEDP) and the maximum descending rate of left
ventricular pressure (−dP/dtmax) [11]. The hearts were
then removed and stored at −80°C for further study.
Examination of Ca2+ homeostasis in cardiomyocytes
Ventricular myocytes were isolated from the rats (n = 6,
in each group) as described previously [12]. In brief, the
hearts were cannulated, and perfused for 10 minutes at
2 mL/min (37°C) with oxygenated Ca2+-free buffer, con-
taining 145 mM NaCl, 5 mM KCl, 1.2 mM MgSO4,
1.4 mM Na2HPO4, 0.4 mM NaH2PO4, 5 mM HEPES,
and 10 mM glucose; pH 7.4, adjusted with NaOH. Then
the hearts were perfused with an enzyme solution, con-
taining 0.6 mg/mL collagenase type II (Invitrogen, USA)
for about 15 min. The ventricular muscle tissue was cut
into small pieces, and the ventricular myocytes were
released by agitating the cell/tissue suspension. After
filtration through a nylon mesh, Ca2+ was gradually
reintroduced up to 1.8 mM in the cell suspension. The
ventricular myocytes were then ready to be used in
further studies.
For the Ca2+ spark imaging, cardiomyocytes were incu-
bated with 10 μM Fluo-4 AM (Invitrogen, USA) in a
normal Tyrode’s solution for 5 min at 37°C, and trans-
ferred into a recording chamber. Cells were perfused with
the Tyrode’s solution for 20 min for de-esterification. SR
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caffeine via a nearby pipette. To control the rest potenti-
ation, experiments were performed after about 30 minutes,
upon reintroduction of Ca2+ to a concentration of 1.8 mM
in each group. Confocal line-scan imaging was performed
using a Leica SP5 confocal microscope (Germany, 40 ×,
1.25 NA) with an excitation at 488 nm. Line-scan images
were acquired at a sampling rate of 1.43 ms per line, along
the longitudinal axis of the cell. Digital image processing
was performed using MATLAB 7.1 (Math Works). For a
minimal detection of Ca2+ sparks, the criteria was set at
greater than 3.8× the standard deviation (SD) of the back-
ground noise over the mean background noise, and Ca2+
sparks were automatically counted with the Sparkmaster
Plug-in for Image [13].Western blot analysis
Western blot analyses (n = 6, in each group) were
conducted as previously described [14] to assess the
expressions of the Ca2+-associated proteins RyR2, SERCA,
NCX1, FKBP12.6, and phospholamban (PLB), and the
phosphorylation status of PLB at serine-16 (PLB-Ser16)
and threonine-17 (PLB-Thr17). In brief, the heart tissue
was homogenized in a cold Tris–HCl buffer (120 mM
NaCl, 1.0%, Triton X-100, 20 mM Tris–HCl, pH 7.5, 10%
glycerol, 2 mM EDTA, protease inhibitor cocktail). Total
protein was quantified using a BCA protein assay kit as
required (CW Bio Tech, 02912E, China). Equal amounts
of protein (40 μg) were separated by SDS-PAGE. After
electrophoresis, proteins were transferred to a polyvinyli-
dene fluoride membrane and blocked with Tris buffered
saline containing 5% skim milk powder and 0.05% Tween
20. Then the corresponding primary antibodies, RyR2
(1:1000, Abcam, USA), SERCA (1:1000, Abcam, USA),
NCX1 (1:300, Santa Cruz, USA), PLB (1:1000, Abcam,
USA), PLB-Thr17 (1:300, Santa Cruz, USA), PLB-Ser16
(1:300, Santa Cruz, USA), and FKBP12.6 (1:1000, R&D,
USA) were added in series. The membranes were incu-
bated with the diluted antibody preparations overnight at
4°C. After washing, the membranes were incubated with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG (H + L) and goat anti-mouse IgG (H + L) antibodies
(1:104; Jackson, USA) for 40 min at room temperature.
The blots were visualized using an enhanced chemilumin-
escence detection kit (Millipore, USA). Target proteins
were quantified and normalized relative to β-actin (1:1000,
Zhongshan, China).Statistical analysis
Data were evaluated by one-way ANOVA expressed as the
mean ± SD. When a significant difference was identified
by ANOVA, a post-hoc analysis was performed using the
Student-Newman-Keuls test. Data were analyzed usingSPSS 13.0 software, and a P-value < 0.05 was considered
significant.
Results
Descriptive variables of diabetic rats
Blood glucose levels were significantly higher in all dia-
betic rats (22.62 ± 5.07 mmol/L) compared with the con-
trol rats (7.57 ± 1.69 mmol/L; P = 0.00), but were not
significantly different among the diabetic groups (P >
0.05; Table 1). Relative to the body weight of the control
rats, that of the streptozotocin-induced diabetic rats was
significantly lower, and progressively decreased from
4 weeks (group B) to 12 weeks (group D, P < 0.05). Heart
weights also decreased during the 12-week development
of diabetes, although the difference was statistically
significant only in group D compared with the control
group (P = 0.013).
Echocardiography measurements
Similar heart rates were observed in all groups (P =
0.627; Table 1). The left ventricular end-diastolic diame-
ters (LVEDD) and left ventricular end-systolic diameters
(LVESD) were comparable in all 3 diabetic groups (P >
0.05). With regard to ejection fraction (EF) and frac-
tional shortening (FS), both showed a trend toward grad-
ual decline in the diabetic rats over the 12 weeks, with
significant reductions (P < 0.05) appearing at the twelfth
week after diabetes was induced (Figure 1). E waves
exhibited a downward trend during the progression of
diabetes, but there were no significant differences among
the diabetic groups (P > 0.05). In group D, there was a
slight but substantial decline in E/A ratio compared with
that in control group (P = 0.027).
Hemodynamic measurements
As diabetes progressed over the experimental period,
LVPSP decreased gradually from group B (4 weeks) to
group D (12 weeks; Figure 2e). Compared with the
controls, LVPSP was reduced significantly in group D
(P = 0.009), which was consistent with the marked
drops in EF and FS. Concurrently, the left ventricular
end-diastolic pressure (LVEDP) increased gradually.
Relative to the control rats, a significant increase in
LVEDP first appeared in group C (8 weeks, P = 0.003,
Figure 2f ), which was earlier than that of the significant
difference in LVPSP. Both + dP/dtmax and –dP/dtmax
began to decrease significantly in group C, and were
sustained in group D, which suggested marked impair-
ments of both systolic and diastolic capabilities of the
diabetic myocardium (Figure 2g and h).
Maintenance of Ca2+ homeostasis
Over the 12-week progression of diabetes, there were
alterations in the properties of Ca2+ sparks (Figure 3).
Table 1 General characteristics and results of echocardiography
Control Diabetic models
Group A Group B Group C Group D
Body weight (g) 589.83 ± 37.4 450.3 ± 52.6a 394.8 ± 62.3a 256 ± 46.3a,b,c
Heart weight (mg) 780 ± 105.2 796.8 ± 104.8 748.5 ± 152.2 595.1 ± 59.6a,b,c
Blood glucose (mmol/L) 7.57 ± 1.69 24.83 ± 6.19a 22.25 ± 5.16a 19.47 ± 2.63a
Echocardiography
Heart rate (beats/min) 420 ± 15 392 ± 41 409 ± 34 388 ± 30
LVEDD (mm) 11.67 ± 2.06 7.7 ± 0.6a 7.8 ± 0.5a 7.5 ± 0.4a
LVESD (mm) 5.84 ± 1.15 3.9 ± 0.3a 4.3 ± 0.7a 4.1 ± 0.6a
Ejection fraction (%) 76.1 ± 4.2 71.4 ± 4.9 71.7 ± 3.8 67.7 ± 5.18a
Fractional shortening (%) 45.4 ± 2.9 41.6 ± 3.7 39.9 ± 3.1 37.6 ± 2.8a
E wave (cm/s) 129.2 ± 6.74 124.8 ± 6.13 120.9 ± 8.32 112.9 ± 5.93
A wave (cm/s) 76.5 ± 9.1 79.3 ± 10.5 73.1 ± 7.58 79.1 ± 5.39
E/A ratio 1.69 ± 0.2 1.56 ± 0.26 1.65 ± 0.17 1.42 ± 0.14a
LVEDD, left ventricle end-diastolic diameter; LVESD, left ventricle end-systolic diameter.
aP < 0.05 compared with control group; bP < 0.05 compared with group B; cP < 0.05 compared with group C.
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cline, beginning at 4 weeks (group B), and was sustained
in groups C (8 weeks) and D (12 weeks; Figure 3b). Con-
currently, relative to the control group the Ca2+ spark
peak amplitude (ΔF/F) was unchanged in group B, but sig-
nificantly increased from group C to group D (Figure 3c).













Figure 1 Echocardiography of the study subjects with ejection fractio
(b) Representative measurement of the parameters. (c) Ejection fraction (EF
A-D. *P < 0.05, compared with group A.significantly and progressively from group B to group
D (Figure 3f ).
In addition, caffeine stimulation caused a sudden and
transient Ca2+ release from the SR and an increase in
intracellular Ca2+ concentration, which represented the
SR Ca2+ load. The SR Ca2+ load showed a marked de-













n and fractional shortening. (a) Representative echocardiograph.























































































Figure 2 Cardiac hemodynamics. The representative hemodynamic curves recorded by polygraphy: (a) Group A; (b) Group B; (c) Group C;
(d) Group D. X-axes represent time in second. The parameters: left ventricular systolic peak pressure (LVPSP) (e), left ventricular end-diastolic
pressure (LVEDP) (f), +dP/dtmax (g), −dP/dtmax (h) in groups A-D. ±dP/dtmax: maximal ascending and descending rates of left ventricular pressure.
*P < 0.05, compared with group A; #P < 0.05, compared with group B; ▲P < 0.05, compared with group C.
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Ca2+ spark rise times nor the full width at half-maximum
amplitude (FWHM) were significantly different in the
different stages of diabetes from that of the control rats
(Figure 3d and e).
Expressions of Ca2+-associated proteins
RyR2, SERCA, and NCX1 are the major channel pro-
teins for Ca2+ flux, and their expressions were analyzedby western blot (Figures 4 and 5). Levels of RyR2 pro-
teins were significantly lower in group B, relative to
those of the control, with progressively less in groups C
and D (Figure 4b). Expressions of FKBP12.6 protein, a
regulatory protein of RyR2, were similar in the control
rats and group B, but significantly less in group C, and
reduced further in group D (Figure 4c). Both SERCA
and NCX1 showed a trend of gradual decline over the
12 weeks in diabetic rats: significantly less in group B
a)
































































































































Figure 3 Ca2+ sparks in groups A-D. (a) Images of Ca2+ sparks; (b) Ca2+ spark frequency; (c) peak amplitude of Ca2+ sparks; (d) FWHM of Ca2+
sparks; (e) rise time; (f) Tau; (g) SR Ca2+ load. *P < 0.05, compared with group A; #P < 0.05, compared with group B; ▲P < 0.05, compared with group C.
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(a) 




Figure 4 RyR2 and FKBP12.6 in groups A-D. (a) Western blots of RyR2, FKBP12.6, and β-actin; (b) ratios of RyR2 to β-actin; and (c) ratios of
FKBP12.6 to β-actin; *P < 0.05, compared with group A; #P < 0.05, compared with group B; ▲P < 0.05, compared with group C.
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C to group D (Figure 5b, 5c). In addition, expressions of
PLB protein, a regulatory protein of SERCA, in group B
were similar to those in the control, but significantly
and progressively higher levels were detected from
group C to group D (Figure 6b). Concurrently, expres-
sions of PLB-Thr17 and PLB-Ser16 proteins were also(a) 
(b)      
Figure 5 SERCA and NCX1 in groups A-D. (a) Western blots of SERCA, N
NCX1to β-actin. *P < 0.05, compared with group A; #P < 0.05, compared witsignificantly less in group B relative to the controls, and
further declines were detected from group C to group
D (Figure 6c, d).
Discussion
The present study assessed changes in Ca2+ homeostasis
and sarcoplasmic reticulum Ca2+-associated proteins in(c)   
CX1, and β-actin; (b) ratios of SERCA to β-actin; and (c) ratios of





Figure 6 PLB, PLB-Thr17 and PLB-Ser16 in groups A-D. (a) Western blots of PLB, PLB-Thr17, PLB-Ser16 and β-actin; Relative ratios of PLB
(b), PLB-Thr17 (c) and PLB-Ser16 (d) to β-actin. *P< 0.05, compared with group A; #P< 0.05, compared with group B; ▲P< 0.05, compared with group C.
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model. Over the 12-week experimental period, the car-
diac function of the diabetic rats gradually worsened,
and this was positively associated with changes in Ca2+
homeostasis. As diabetes progressed, Ca2+ spark proper-
ties changed and levels of RyR2, SERCA, NCX1, and
FKBP12.6 decreased.
With the development of diabetes, cardiac function of
the rats gradually declined. Echocardiography showed
impairments of systolic and diastolic functions, reflected
by marked reductions in EF, FS, and E/A ratio, which
concurrently appeared at the twelfth week.
Hemodynamic measurements are more sensitive than
echocardiography in the detection of early cardiac dys-
function. The results of hemodynamic measurements in
this study indicated that diastolic and systolic myocardial
performance was depressed at the eighth week of dia-
betes, as determined by significant reductions in ± dP/
dtmax. Furthermore, a significant increase in LVEDP
appeared at the eighth week of diabetes, earlier than the
significant decrease in LVPSP at 12 weeks. These find-
ings suggest that cardiac dysfunction in diabetic ratsinitially started with left ventricular diastolic function
and then proceeded to systolic function, in agreement
with previous studies [15]. Furthermore, we noticed that
cardiac dysfunction correlated with changes in Ca2+
homeostasis over the 12 weeks.
Our data showed that Ca2+ spark properties experi-
enced a series of changes in a time-dependent manner,
associated with the duration of diabetes. The major
changes included a gradual decline in both the Ca2+
spark frequency and SR Ca2+ load, and simultaneously
an increase in both the Tau and peak amplitude of Ca2+
sparks. Ca2+ spark peak amplitudes and the FWHM
reflected the shapes and sizes of Ca2+ sparks in the different
diabetic periods. A decrease in Ca2+ spark frequency could
indicate a decline in both SR Ca2+ release and global intra-
cellular Ca2+ concentration during excitation-contraction
coupling, which might account for, at least in part, the
gradual impairment of systolic function in the diabetic rats.
An increase in Tau (i.e., the Ca2+ spark decay time con-
stant) could indicate a decline of Ca2+ efflux rate, which
might partly account for the reduction of –dP/dtmax, as well
as the impairment of diastolic function in the diabetic rats.
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period, and might be partly responsible for the drop
in Ca2+ spark frequency in the diabetic rats. It was
also noticed that cardiac dysfunction occurred after
alterations in Ca2+ handling. This implies that the depres-
sion of cardiac function may result, at least in part, from
progressive Ca2+ mishandling.
We also showed that levels of the major Ca2+ channel
proteins, RyR2, SERCA, and NCX1 declined in a time-
dependent manner with the progression of diabetes.
Since these declines appeared earlier than Ca2+ mis-
handling, Ca2+ mishandling could partly result from the
changes in channel protein levels. Those of RyR2, the
major Ca2+ release channel protein on the SR, exhibited
a downward trend in the diabetic rats, which was pri-
marily responsible for the decrease in Ca2+ diffusion
away from the SR and Ca2+ spark decay.
Simultaneously, the levels of FKBP12.6, the regulatory
protein of RyR2, also declined in a time-dependent man-
ner in the diabetic rats. FKBP12.6 is a small cytosolic
protein which binds to the RyR2 protein. The binding
stabilizes the RyR2 in the channel’s closed state during
diastole [16]. A reduction of FKBP12.6 protein impairs
the binding and increases the open state of the RyR2
during diastole, thereby leading to an aberrant increase
in diastolic Ca2+ leak [16]. Diastolic Ca2+ leak results in
a reduction of SR Ca2+ load and Ca2+ spark frequency,
and an increase in the Tau, thereby contributing to the
impairment of left ventricular systolic and diastolic
functions.
SERCA is another major Ca2+ channel protein on the
SR, and is responsible for Ca2+ reuptake (70-92%) into
the SR [17]. NCX1 is the major Ca2+ channel protein on
sarcolemma, and is responsible for Ca2+ efflux from
cardiomyocyte during diastole. Reuptake or efflux of
Ca2+ via SERCA or NCX1 decreases the Ca2+ concentra-
tion in cardiomyocytes, which facilitates myocardial
relaxation and maintains the Ca2+ content in the SR.
Decreases in SERCA and NCX1 in this study were pri-
marily the result of intracellular accumulation of Ca2+
during diastole and a prolonged Tau, which corre-
sponded to the impairment of left ventricular diastolic
function in the development of diabetes. Moreover, the
reduction in SERCA protein was also related to a de-
crease in the Ca2+ reuptake rate, leading to a decline of
SR Ca2+ load.
The regulation of SERCA is dependent on interaction
with PLB. It has been confirmed that PLB acts as an
inhibitor on SERCA, whereas phosphorylation of PLB
can attenuate the inhibition and induce a substantial in-
crease in Ca2+ flux via SERCA [18-20]. Upon binding
with PLB, SERCA loses activity as Ca2+ reuptake de-
creases. In the present study, the PLB protein levels pro-
gressively increased over the experimental period, andphosphorylation of PLB experienced a gradual decline in
the diabetic rats. Both these changes in PLB and its
phosphorylation status attenuated the Ca2+ flux by
SERCA during diastole in diabetic rats, which was also
related to the impairment of left ventricular diastolic
function.
Conclusions
The present study showed that Ca2+ sparks decay with pro-
gression of diabetes, accompanied by a successive impair-
ment of cardiac function. Alterations in Ca2+ -associated
protein levels were detected in the development of diabetes,
which partly accounted for the Ca2+ spark decay and
subsequent cardiac dysfunction. These results may indi-
cate a possible molecular mechanism underlying cardiac
dysfunction in the diabetic rat model, and thereby con-
tribute to the search for a possible intervention. Further
studies are warranted to investigate the signal pathways
responsible for alterations in the levels of Ca2+-associ-
ated proteins.
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